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In their study on Intrauterine device use (IUD) and risk of cervical cancer published in 
The Lancet Oncology, Xavier Castellsagué and colleagues1 claimed that their work 
provides evidence that IUD use might reduce the risk of developing cervical to solid 
evidence that IUD use might reduce the risk of developing cervical cancer.  
The authors pursued alternative explanations using stratified analyses with possible 
confounders and investigated plausible mechanisms for the reported effect. They were 
right to have done so, not only for scientific reasons but also because studies such as 
these are rapidly picked up by the media, who sometimes draw premature or unrealistic 
conclusions from such data. Additionally, this study has important commercial 
implications; therefore, caution in the interpretation of these results is necessary. We 
would like to put forward some ideas in this letter that might help to understand the 
results better. 
Our main concern is related to the ever/never classification of exposure variables. 
Although some of the crude analyses are presented with IUD use as a categorical 
variable, the main results are estimated and presented with ever/never use. 
Oral Contraceptive use is clearly related to cervical cancer2 and therefore its inclusion in 
the main analysis would have yielded better adjusted results. However, oral 
contraceptive use cannot be evaluated precisely without simultaneously taking duration 
of exposure and timing of exposure into account, because induction and latency periods 
are key issues in cancer epidemiology.3 Therefore, the ever/never stratification of oral 
contraceptive use is probably not precise enough to adjust for confounding. A lower 
oral contraceptive use in long term IUD users than in short-term IUD users or those who 
have never used an IUD cannot be completely ruled out as an alternative explanation for 
the lower cervical cancer risk seen in long-term IUD users.  
When data were stratified by duration of oral contraceptive exposure (0, 1, 2-4, 5-9, and 
≥10 years; presented in the web appendix1), most of the associations were not 
significant, and there was even one positive association for IUD users that used oral 
contraceptives for 2-4 years, which was not discussed in the main Article.   
Furthermore, the associations between IUD use and cervical cancer in those who have 
never used oral contraceptives are not adjusted for other important confounders, such as 
alternative family planning methods used by those not using IUDs (eg, other hormonal 
methods that are more prevalent in developing countries), number of sexual partners, 
and smoking.  
The imprecise measurement of a crucial confounder such as oral contraceptive use is the 
main weakness of this study. A better defined reference category of exposure would 
have been much more informative. 
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